AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 222 min read

PDS Biotechnology gets 19.9% Nant Capital stake

PDS Biotechnology (PDSB) disclosed that Nant Capital, led by Patrick Soon-Shiong, acquired a 19.9% stake in the company. Nant Capital purchased 13,005,334 shares and warrants for $0.2825 per share. The investment includes a milestone closing contingent on PDS0301's Phase 3 trial submission to the FDA, with Nant Capital obligated to invest $10M. Soon-Shiong and James Banaag joined PDS Biotechnology's board.

Original reporting
stocktitan.net
Published Sep 22, 2026, 2:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 3:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$PDSB
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Med
01

Why it matters

The filing introduces a new large shareholder with board influence and a contingent $10M milestone purchase, which could affect governance and future financing.

02

Market read

Primary disclosure of a significant ownership stake and financing terms for a microcap biotech, modest trading relevance.

03

What to watch

Future FDA filing milestone could trigger larger capital moves if successful.

Relevance 6/10Novelty 6/10Timing: post-September 7 2026 filing

Background

PDS Biotechnology filed a Schedule 13D reporting a 19.9% stake acquisition by Nant Capital, board appointments, and a PIPE financing agreement.

Market effects

Sector

Potential signal for biotech financing activity and board composition trends.

Regional

Limited to US biotech microcap segment.

Global

Low global impact.

Counterpoint

What could challenge this read

Stake size may not move price significantly; market may already price in the investment.

Key entities

  • company
    PDS Biotechnology Corporation

    Biotech firm issuing common stock and warrants.

  • investor
    Nant Capital, LLC

    Investor acquiring 19.9% stake and board seats.

Read at source← All news

Related articles

SEP 22
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K2 min
SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min
SEP 8
$PDSBHighAI 8/10

80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment

PDS Biotech (PDSB) secured a PIPE financing of up to $22.55M led by Nant Capital, with an initial closing of $11.55M expected by September 11, 2026. The funds will support late-stage development of PDS0301, following Phase 2 trial data showing 80% 24-month survival in 22 metastatic colorectal cancer patients. Nant Capital may designate two board members, including Dr. Patrick Soon-Shiong, while owning at least 15% of the common stock.

stocktitan.net2 min
AUG 19
$PDSBLow

PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs

PDS Biotechnology (PDSB) announced CFO Lars Boesgaard's resignation effective September 12, 2026. CEO Frank Bedu-Addo will serve as interim Principal Financial Officer, while Janetta Trochimiuk becomes interim Principal Accounting Officer with a $279,519.57 annual salary. Boesgaard's departure is not due to disagreements. Trochimiuk remains eligible for future equity awards.

stocktitan.net1 min